Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598838 | 0.83 | RAB9A (1.00) | RAB9ANPC1PTPN1KMT2ALMNA | |
| SCHEMBL2051943 | 0.82 | RAB9A (0.75) | RAB9ANPC1KMT2ALMNACYP1A2 | |
| SCHEMBL6011931 | 0.82 | RAB9A (0.75) | RAB9ANPC1KMT2ALMNACYP1A2 | |
| Bromide SCHEMBL30883373 | 0.81 | RAB9A (0.97) | RAB9ANPC1PTPN1KMT2ALMNA | |
| SCHEMBL7820941 | 0.81 | RAB9A (0.73) | RAB9ANPC1LMNACYP1A2CYP2C19 | |
| Iodide SCHEMBL28448392 | 0.81 | RAB9A (0.69) | RAB9ANPC1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL29017606 | 0.80 | RAB9A (0.73) | RAB9ANPC1KMT2ACYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL11622188 | 0.80 | RAB9A (0.73) | RAB9ANPC1KMT2ALMNACYP1A2 | |
| SCHEMBL29986829 | 0.80 | RAB9A (0.73) | RAB9ANPC1KMT2ALMNACYP1A2 | |
| SCHEMBL30333799 | 0.80 | RAB9A (0.73) | RAB9ANPC1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211731-A1 | New substituted pyridine or piperidine compounds | LES LABORATORIES SERVIER (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20050004168-A1 | New substituted pyridine or piperidine compounds | METH-COHN OTTO (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-1050531-B1 | Pyridine and piperidine derivatives for treating neurodegenerative diseases | SERVIER LAB (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-6638946-B2 | 1-(4-bromophenyl)-2-(1-methyl-2-piperidinyl)-1-ethanone, for example; treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Korsakoff's disease and frontal lobe and subcortical dementias | LES LABORATOIRES SERVIER (FR) | 2003-10-28 | — | — | US | disclosed |
| US-20030181484-A1 | New substituted pyridine or piperidine compounds | METH-COHN OTTO (GB) | 2003-09-25 | — | — | US | disclosed |
| US-6511992-B2 | For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging | LES LABORATORIES SERVIER (FR) | 2003-01-28 | — | — | US | disclosed |
| US-20020040036-A1 | New substituted pyridine or piperidine compounds | ADIR ET COMPAGNIE | 2002-04-04 | — | — | US | disclosed |
| US-20020035123-A1 | New substituted pyridine or piperidine compounds | ADIR ET COMPAGNIE | 2002-03-21 | — | — | US | disclosed |
| US-6323220-B1 | COGNITION ACTIVATORS AND TREATMENT OF NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181484-A1 | New substituted pyridine or piperidine compounds | CNR1, HRH4, OPRD1 | RAB9A 1163/4885NPC1 2461/4885TLR7 787/4885 |
| US-20060211731-A1 | New substituted pyridine or piperidine compounds | HRH3, P2RY1, CHRM1 | RAB9A 1017/4885NPC1 2862/4885TLR7 686/4885 |
| US-20050004168-A1 | New substituted pyridine or piperidine compounds | HRH3, HRH4, HRH1 | RAB9A 990/4885NPC1 2766/4885TLR7 817/4885 |
| US-20020035123-A1 | New substituted pyridine or piperidine compounds | OPRD1, CNR1, HRH4 | RAB9A 1212/4885NPC1 2642/4885TLR7 708/4885 |
| US-20020040036-A1 | New substituted pyridine or piperidine compounds | CNR1, OPRD1, OPRK1 | RAB9A 1088/4885NPC1 2469/4885TLR7 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.